Analyzing NeurAxis (NRXS) and Its Peers

NeurAxis (NASDAQ:NRXS) is one of 74 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its competitors? We will compare NeurAxis to similar businesses based on the strength of its profitability, earnings, dividends, risk, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for NeurAxis and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
NeurAxis Competitors	227	714	1893	98	2.64

As a group, “Electromedical equipment” companies have a potential upside of 39.08%. Given NeurAxis’ competitors higher possible upside, analysts clearly believe NeurAxis has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares NeurAxis and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeurAxis	$2.46 million	-$14.63 million	-0.65
NeurAxis Competitors	$964.46 million	$82.03 million	6.30

NeurAxis’ competitors have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares NeurAxis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-594.55%	N/A	-899.27%
NeurAxis Competitors	-333.03%	-41.70%	-24.26%

Insider & Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 43.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NeurAxis competitors beat NeurAxis on 9 of the 12 factors compared.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.